Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 9/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5034356 | 0.91 | ROCK2 (0.42) | ROCK2ROCK1MAPK1 | |
| SCHEMBL13927708 | 0.89 | MAPK1 (0.43) | ROCK2ROCK1ADORA2AMAPK1 | |
| SCHEMBL5034325 | 0.89 | MAPK1 (0.43) | ROCK2ROCK1ADORA2AMAPK1 | |
| SCHEMBL6426273 | 0.87 | MAPK1 (0.41) | ROCK2ROCK1ADORA2AMAPK1 | |
| SCHEMBL5030003 | 0.87 | MAPK1 (0.41) | ROCK2ROCK1ADORA2AMAPK1 | |
| SCHEMBL6428698 | 0.86 | GPR88 (0.44) | ROCK2ROCK1MAPK1ALDH1A1 | |
| SCHEMBL5030009 | 0.86 | MAPK1 (0.43) | ROCK2ROCK1ADORA2AMAPK1 | |
| SCHEMBL5031204 | 0.85 | ROCK2 (0.41) | ROCK2ROCK1ADORA2AMAPK1 | |
| SCHEMBL6428627 | 0.85 | MAPK1 (0.41) | ROCK2ROCK1ADORA2AMAPK1 | |
| SCHEMBL5029985 | 0.85 | PAK4 (0.45) | ROCK2ROCK1ADORA2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | CNKSR1, NR3C2, CSNK2B | ROCK2 503/4885ROCK1 768/4885ADORA2A 1738/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | ROCK2 560/4885ROCK1 826/4885ADORA2A 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.